• Je něco špatně v tomto záznamu ?

Long-Term Opioid Agonist Treatment Participation after First Treatment Entry is Similar across 4 European Regions but Lower in Non-Nationals

C. Nordt, L. Wiessing, W. Kuijpers, J. Wisselink, A. Espelt, MT. Brugal, V. Mravčik, B. Nechanská, E. Seifritz, M. Herdener,

. 2018 ; 24 (4) : 173-183. [pub] 20180717

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000551

Grantová podpora
NV16-28157A MZ0 CEP - Centrální evidence projektů

Heroin users in opioid agonist treatment (OAT) show markedly reduced heroin consumption, less crime and a lower mortality rate. However, the extent of long-term OAT participation over subsequent treatment episodes remains unclear. We analysed the annual proportion of patients in treatment (at least 1 day) since the start of first OAT in 4 European regions: Barcelona (BA) 1996-2012: 8,602 patients; Czech -Republic (CZ) 2000-2014: 4,377 patients; Netherlands (NL) 1994-2014: 33,235 patients, Zurich (ZU) 1992-2015: 11,795. We estimated the long-term decline of treatment need due to mortality or abstinence and also a "nuisance" short-term decline until the equilibrium level of cycling in and out of OAT is reached to obtain the adjusted treatment participation value. The adjusted treatment participation was around 50% (BA: 47.4-51.4%; CZ: 49.8-53.9%; NL: 52.3-54.0%; ZU: 46.4-49.3%), and the annual decline of treatment need was close to 4%. Non-nationals (NL patients with a migrant background) showed substantial lower adjusted treatment participation (rate ratio BA: 0.059-0.343; NL: 0.710-0.751; ZU: 0.681-0.797; CZ: n.a.). Our method may provide a policy-relevant indicator of long-term provision, quality and access to OAT following first treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000551
003      
CZ-PrNML
005      
20190118111854.0
007      
ta
008      
190107s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000490529 $2 doi
035    __
$a (PubMed)30016806
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Nordt, Carlos $u Center for Addictive Disorders, Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
245    10
$a Long-Term Opioid Agonist Treatment Participation after First Treatment Entry is Similar across 4 European Regions but Lower in Non-Nationals / $c C. Nordt, L. Wiessing, W. Kuijpers, J. Wisselink, A. Espelt, MT. Brugal, V. Mravčik, B. Nechanská, E. Seifritz, M. Herdener,
520    9_
$a Heroin users in opioid agonist treatment (OAT) show markedly reduced heroin consumption, less crime and a lower mortality rate. However, the extent of long-term OAT participation over subsequent treatment episodes remains unclear. We analysed the annual proportion of patients in treatment (at least 1 day) since the start of first OAT in 4 European regions: Barcelona (BA) 1996-2012: 8,602 patients; Czech -Republic (CZ) 2000-2014: 4,377 patients; Netherlands (NL) 1994-2014: 33,235 patients, Zurich (ZU) 1992-2015: 11,795. We estimated the long-term decline of treatment need due to mortality or abstinence and also a "nuisance" short-term decline until the equilibrium level of cycling in and out of OAT is reached to obtain the adjusted treatment participation value. The adjusted treatment participation was around 50% (BA: 47.4-51.4%; CZ: 49.8-53.9%; NL: 52.3-54.0%; ZU: 46.4-49.3%), and the annual decline of treatment need was close to 4%. Non-nationals (NL patients with a migrant background) showed substantial lower adjusted treatment participation (rate ratio BA: 0.059-0.343; NL: 0.710-0.751; ZU: 0.681-0.797; CZ: n.a.). Our method may provide a policy-relevant indicator of long-term provision, quality and access to OAT following first treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a opioidní analgetika $x aplikace a dávkování $7 D000701
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a databáze faktografické $x trendy $7 D016208
650    _2
$a rozvrh dávkování léků $7 D004334
650    12
$a emigranti a imigranti $7 D054242
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Nizozemsko $x epidemiologie $7 D009426
650    _2
$a opiátová substituční terapie $x metody $x trendy $7 D058850
650    _2
$a poruchy spojené s užíváním opiátů $x diagnóza $x epidemiologie $x terapie $7 D009293
650    _2
$a zapojení pacienta $x metody $x trendy $7 D010358
650    _2
$a Španělsko $x epidemiologie $7 D013030
650    _2
$a Švýcarsko $x epidemiologie $7 D013557
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wiessing, Lucas $u European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
700    1_
$a Kuijpers, Wil $u Stichting Informatievoorziening Zorg, Houten, the Netherlands.
700    1_
$a Wisselink, Jeroen $u Stichting Informatievoorziening Zorg, Houten, the Netherlands.
700    1_
$a Espelt, Albert $u Agència de Salut Pública de Barcelona, Barcelona, Spain. Facultat de Ciències de la Salut de Manresa, Universitat de Vic Universitat Central de Catalunya (UVicUCC), Manresa, Spain. CIBER de Epidemiologia y Salud Pública, Madrid, Spain.
700    1_
$a Brugal, M Teresa $u Agència de Salut Pública de Barcelona, Barcelona, Spain.
700    1_
$a Mravčik, Viktor $u Department of Addictology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague, Prague, Czech Republic. National Monitoring Centre for Drugs and Addiction, The Office of the Government of the Czech Republic, Prague, Czech Republic. National Institute of Mental Health, Klecany, Czech Republic.
700    1_
$a Nechanská, Blanka $u Department of Addictology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague, Prague, Czech Republic. National Institute of Mental Health, Klecany, Czech Republic. Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic.
700    1_
$a Seifritz, Erich $u Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
700    1_
$a Herdener, Marcus $u Center for Addictive Disorders, Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
773    0_
$w MED00007942 $t European addiction research $x 1421-9891 $g Roč. 24, č. 4 (2018), s. 173-183
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30016806 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118112109 $b ABA008
999    __
$a ok $b bmc $g 1364610 $s 1038674
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 24 $c 4 $d 173-183 $e 20180717 $i 1421-9891 $m European addiction research $n Eur Addict Res $x MED00007942
GRA    __
$a NV16-28157A $p MZ0
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace